[go: up one dir, main page]

WO2001012191A3 - Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid - Google Patents

Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid Download PDF

Info

Publication number
WO2001012191A3
WO2001012191A3 PCT/GB2000/003112 GB0003112W WO0112191A3 WO 2001012191 A3 WO2001012191 A3 WO 2001012191A3 GB 0003112 W GB0003112 W GB 0003112W WO 0112191 A3 WO0112191 A3 WO 0112191A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucocorticoid
benzothiazolone
aminoethyl
pharmaceutical compositions
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003112
Other languages
French (fr)
Other versions
WO2001012191A2 (en
Inventor
Francis Ince
John Dixon
Philip Holt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to AU64601/00A priority Critical patent/AU6460100A/en
Publication of WO2001012191A2 publication Critical patent/WO2001012191A2/en
Publication of WO2001012191A3 publication Critical patent/WO2001012191A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being a glucocorticoid, for use in the treatment of obstructive airways diseases.
PCT/GB2000/003112 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid Ceased WO2001012191A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64601/00A AU6460100A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902936-5 1999-08-18
SE9902936A SE9902936D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO2001012191A2 WO2001012191A2 (en) 2001-02-22
WO2001012191A3 true WO2001012191A3 (en) 2001-09-07

Family

ID=20416694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003112 Ceased WO2001012191A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid

Country Status (4)

Country Link
AR (1) AR025340A1 (en)
AU (1) AU6460100A (en)
SE (1) SE9902936D0 (en)
WO (1) WO2001012191A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329586T3 (en) 2003-11-21 2009-11-27 Theravance, Inc. COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE BETA2 ADRENERGIC RECEIVER AND ANTAGONIST OF THE MUSCARINE RECEIVER.
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EP2303873A4 (en) 2008-06-18 2012-01-04 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNES P.J.: "New therapies for chronic obstructive pulmonary disease.", THORAX, (1998) 53/2 (137-147)., XP000986442 *
IKEDA A. ET AL: "Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease.", DRUGS AND AGING, (1998) 12/2 (129-137)., XP000986468 *
KERSTJENS H A ET AL: "Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group.", THORAX, (1994 NOV) 49 (11) 1109-15., XP000986460 *
LURIE A. ET AL: "Long-term management of reversible obstructive airways disease in adults.", LUNG, (1990) 168/SUPPL. (154-167)., XP000986437 *

Also Published As

Publication number Publication date
WO2001012191A2 (en) 2001-02-22
SE9902936D0 (en) 1999-08-18
AR025340A1 (en) 2002-11-20
AU6460100A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
IL170120A (en) 1,2,4-triazine compounds, their use for preparation of medicaments for treating or preventing hiv, pharmaceutical compositions comprising the same and processes for their preparation
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2345121A1 (en) Pharmaceutical composition for the treatment of acute disorders
EE200000532A (en) Use of pyrimidine derivatives for the preparation of a medicament for the treatment of HIV infection, a compound, a pharmaceutical composition containing it, a process for the preparation of a compound and a composition, and a combination preparation for use in
EE05404B1 (en) A quinuclidine derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it
CA2345064A1 (en) Fentanyl composition for the treatment of acute pain
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
IL131010A (en) Aryl sulfonamides and analogues thereof, processes for their preparation and pharmaceutical compositions comprising them in the treatment of neurodegenerative diseases
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
AU6404398A (en) New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
WO2001012167A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist
GB0029936D0 (en) A pharmaceutical formulation suitable for the treatment of hepititis B, hepititis C and other viral infections of the liver and a process for its preparation
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2001011933A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a pde4 inhibitor
WO2001012191A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid
WO2004014293A3 (en) Combination of anti-muscarinic agents and non-glucocorticoid steroids
WO2001012192A3 (en) Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
AU8015398A (en) Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
HUP0003634A3 (en) Use of thiazolidinedione and sulphonylurea derivatives for the preparation of pharmaceutical compositions treating diabetes
EE200200260A (en) Pyrazolo [1,5-d] [1,2,4] triazine derivative, its preparation and its use in the preparation of a medicament for the enhancement of cognition, and a pharmaceutical composition containing it

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09674087

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP